Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Multiple Myeloma 17Carcinoma, Hepatocellular 5Recurrence 4Neoplasms, Plasma Cell 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Liver Neoplasms 3Sarcoma 2NSCLC 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Leiomyosarcoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Glioblastoma 1Extrapancreatic Neuroendocrine Tumor 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Gefitinib 5icotinib 4Pemetrexed 4Docetaxel 4camrelizumab 3apatinib 3anlotinib 3aflutinib 3Erlotinib Hydrochloride 3osimertinib 2dacomitinib 2Thalidomide 2Radiosurgery 2Drug Therapy 2Carboplatin 2Afatinib 2trilaciclib 1spartalizumab 1pembrolizumab 1nimotuzumab 1famitinib 1envafolimab 1Vinorelbine 1Tyrosine Kinase Inhibitors 1S 1 (combination) 1Radiofrequency Ablation 1Microphysiological Systems 1Immune Checkpoint Inhibitors 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × NSCLC × Thalidomide × Clear all
NCT02778893 2016-05-20

Conmana Combined With Thalidomide to Treat NSCLC

Henan Provincial People's Hospital

Phase 4 Unknown
67 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡